April 25, 2012 Latest News

  • BBVA earns €1.005 billion in the first quarter
  • BBVA’s profit for the first quarter of 2012 was €1.005 billion, which is 12.6% less than the same period last year but exceeds that of the two previous quarters. Gross income rose 3.5% to €5.45 billion, supported by firm recurring income in all the regions where the Group operates.
  • By Business Updates
  • 3-GIS to Exhibit and Present at GISWORX 2012
  • 3-GIS, a GIS software solutions company based in Decatur, Alabama will exhibit at the GISWORX Conference and Expo in Dubai. 3-GIS' Chief Technical Officer, Tommy Siniard and Program Director, Lee Nelson, will also be presenting. The conference will be held May 1-3, 2012 at the Convention Centre of Al Bustan Rotana Hotel in Dubai.
  • By 3-gis
  • 500 Green Meeting Consultants to be Trained by German Convention Bureau
  • Meeting planners are increasingly interested in hosting green meetings and events. The German Convention Bureau (GCB) is helping by training up to 500 meetings consultants in sustainability best practices who can assist U.S. and global planners and organizations looking to host green meetings in Germany. This latest move is part of Germany's and the GCB's ongoing commitment to sustainability.
  • By Clareville
  • Awasi: Selected As One Of The Robb Report´s Top 100 World Resorts
  • Awasi, Is Very Proud To Announce, It Has Been Selected As One Of The Robb Report´s Top 100 World Resorts. The Robb Report, Being One Of The Most Respected Publications From The Luxury Segment, Has Included Awasi In A Group Of Exceptional And Exclusive Properties From All Over The World, For Its Upcoming May 2012 Issue.
  • By Awasi
  • Edmond Yunis to speak at Antibody Conference June 7-8, 2012 in San Diego, CA
  • Edmond Yunis, Professor of Pathology at Harvard Medical School and Chief of Immunogenetics at the Dana-Farber Cancer Institute will give a featured presentation on "Humoral Mechanisms and Molecular Signatures of Latent Tuberculosis Infection" at GTC's Antibody Design and Discovery Conference (June 7-8, 2012 in San Diego, CA).
  • By Gtcbio
  • Danish biotech company Azanta gets orphan drug approval by the EU commission
  • For years, Danish head and neck cancer patients have had their chances of overcoming their cancer therapy improved by an add-on treatment to radiotherapy. Danish biotech company Azanta has now received Orphan Drug Designation, which will facilitate the dissemination of the treatment for the benefit of a wide range of patients worldwide.
  • By Azanta